<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64624</article-id><article-id pub-id-type="doi">10.7554/eLife.64624</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>ARL3 activation requires the co-GEF BART and effector-mediated turnover</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-214130"><name><surname>ElMaghloob</surname><given-names>Yasmin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-67298"><name><surname>Sot</surname><given-names>Begoña</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-214131"><name><surname>McIlwraith</surname><given-names>Michael J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-214132"><name><surname>Garcia</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-214133"><name><surname>Yelland</surname><given-names>Tamas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-185212"><name><surname>Ismail</surname><given-names>Shehab</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4150-1077</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Structural biology</institution>, <institution>Beatson Institute for Cancer Research</institution>, <addr-line><named-content content-type="city">Glasgow</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Nanobiosystems</institution>, <institution>IMDEA Nanoscience</institution>, <addr-line><named-content content-type="city">Madrid</named-content></addr-line>, <country>Spain</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1160"><name><surname>Pfeffer</surname><given-names>Suzanne R</given-names></name><role>Reviewing editor</role><aff><institution>Stanford University School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>shehab.ismail@glasgow.ac.uk</email> (SI);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>01</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e64624</elocation-id><history><date date-type="received"><day>04</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>12</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, ElMaghloob et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>ElMaghloob et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64624-v1.pdf"/><abstract><p>The ADP-ribosylation factor-like 3 (ARL3) is a ciliopathy G-protein which regulates the ciliary trafficking of several lipid-modified proteins. ARL3 is activated by its guanine exchange factor (GEF) ARL13B via an unresolved mechanism. BART is described as an ARL3 effector which has also been implicated in ciliopathies, although the role of its ARL3 interaction is unknown. Here we show that, at physiological GTP:GDP levels, human ARL3GDP is weakly activated by ARL13B. However, BART interacts with nucleotide-free ARL3 and, in concert with ARL13B, efficiently activates ARL3. In addition, BART binds ARL3GTP and inhibits GTP dissociation, thereby stabilising the active G-protein; the binding of ARL3 effectors then releases BART. Finally, using live cell imaging, we show that BART accesses the primary cilium and colocalises with ARL13B. We propose a model wherein BART functions as a <italic>bona fide</italic> co-GEF for ARL3 and maintains the active ARL3GTP, until it is recycled by ARL3 effectors.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>A17196</award-id><principal-award-recipient><name><surname>Ismail</surname><given-names>Shehab</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for: Figures 1A and 1B, Figures 2B,  2C, 2D, 2E, and 2F, Figures 3A,3B, 3C, 3D, 3F, Figures 4A, 4B, and 4C and Figure 5B, 5C</p></sec><supplementary-material><ext-link xlink:href="elife-64624-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>